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Many patients are accepted for cardiac transptanMon during a 
period of clintcat tnstabiliiy sssorialed Glh a high rirk oC death. 
even though mmt can he discharged home to await transplanta- 
tion. As the wa%ing listslengthen, priority is awarded salely on the 
basisaltk waiting time of oulplknts, who nmv usuatly uade~o 
transptantaltbn atIer they have atready survived n m@jar period of 
jeopardy. To determine the impact of the current naiting times 
and ptiorily system an Ihe previously expeeled benefit offered h) 
transplantatlan, l-year actuarial survival wilhoat tmnsiplaaatiaa 
was recakak&l &or each month without traasplantaWm Far ‘14 
pat+otial undiiates with an ejeelion fraclion of 0.17 f 0.05 
dtm’gfd oa taitorad medical therapy aRer evahmtion. These 
data ~iere compared with the l.ycnr surriral da% of BY %tp=. 
tkuts who uwhwrnt t aarplantatioa. 
Musrial surviM aAer 1 :rar ~a.5 67% on tailored tgerapy 
compared with 86% atlrr transplantation tp = 0.W;. Deata 
uithout transplanm.tian VP-) sudden in 13 at51 parienw. resulting 
Cmm hemud~aamk demmpencation in 8. Far outpatienls already 
surviving 6 moMw aithaat transplaatattan, actuarial surrival 
GW the ne*i I2 months was 83% without traiaplantation. Thus. 
the expec<cd impm$ement in surGval aller transplantation wuutd 
be cnl~ 55 over the auhsequenl )ezr COF palien& raiting 6 
months. ahirh ir the waiting time Iw many oa@aGots. Such 
parifnls should ix rpe~~Iaated to dewmine whether tranrganta- 
lion remains indicated during !b next ! ear. 
Many patients with hean failure are referred to ~ranspl’rnt 
centers for evaluation during a period of deteriontwn when 
the mortality fate is high without transplantation. whether or 
not~he patient isactually ona waiting list. For such patients. 
tailored therapy with high doses of vasodilators and diuretic 
drugs oftenallows stabiliradon and hospital discharge before 
transplantation (1.2). Because of the increasing demand for 
transplankkm in the setting of a relatively fixed supply of 
donor hearts, the avenge waiting time for outpatientr has 
lengthened to almost b months. frequently to > I yenr 131. 
Transplantation in such patients is thus performed in a group 
selected by having already wrvived for an wended period 
that encompasses their greatest interval risk because ihe 
heart failure survival curve falls most steeply early after 
rckrral (41. 
The current national policy awards outpatient priority 
solely on the hasis of waiting time. For patiems surviving 
after months on the wailing list. stabilizatmn and clinical 
imprvrrmcnt frequently occur so that functional capacity is 
similar to that after transplantation 12.5). Although these 
buwi\or\ receive the highesl outpalient priority for the 
limlted donor hearts. :he relative beaefit of their late trans- 
plamation ha% nor been determined. 
The purpose of this study was to determme subsequent 
survival on tailored medical therapy after evaluakm as a 
function of the length of time already survived without 
trancplnntatmn to contrast the expecled survival benetil 
5x1 lzttc transplantation with the survival be&t expected if 
transplantation were performed ill the time of initial listing. 
It WI\ hypotheuzed tbal the difference between subsequent 
\ur\wwI wilh ud withau! transplantation would decline a$ 
the wamng time increated. 
Methods 
Study patients (Table I). All patients with heart failure 
referred to rhis cardiac rranspkunation prosam since I9R5 
have undergone a standardized baseline evaluation. includ- 
ing clinic;1 assessmenl. echocardiograpky and coronary 
:cteriogr:rphy and cndomyuc;trdiul biopsy tt’indicalcd. Len 
~~entrtcul:tr cjcction fraction I\ cidculutcd hum radmnuclidc 
;mgiagraphy m mutt p;mcnt% and frum two.dimcnsionnl 
echoc;mhopruph~ in \ume patients with nonischcmic cardio- 
myopthy. .4<1!btty !umtattcn. orlhupnw :md :tgh!Glcd 
wtott~ conpcstton c&np rplanchnic discomfort or pcriph- 
crai cdcma ure grnded un a scale of 0 to 4 sp~itically 
doitgcd for’hts group ofpaticutr (!I. Baseline hcmodynam- 
its arc detctmined from the results of right henrt cntheter- 
IL&~ perltirmed while the pmicnt is ta:iciving nil prcvi- 
ously prc\crihcd medic;tl thcntpy. 
For this sludy. pmicnt5 0% _‘,. -.UIYdtcd n~twccn Jnly lYH.5 nnd 
June IYXY were included ir they wcrc > IX yr.ar, of age and 
had un cJcction fraction c!!t% and a history of dccumpcn. 
salion with NW York Heart Assomation junctional cluss 111 
or IV symptoms and could he dtv&uucd humc after uccep- 
tan~e as a potenti;tl c;tr&c transplant candidate. Paticnih 
with noniwhcmic cardiomyopathy of reccm onwt (~6 
months1 whose condition could bc rtuhihrcd wcrc nut in. 
cludcd hecause of the variahlc time and sta~ub of prcaentc- 
lion tin some ~itsca not rcquirutp current hemodynamic 
mcasurcmcnta despite previous comprrlmiacl attd the high 
incidcncc of 5ponteneous improvsmcnt 16). P;uienls wcrc 
excluded if they had srandard contmindic;vion\ that wcrc 
considered sufficient to prccludc any considcmtinn a\ 21 
candidate during the ne?;l h months. including patient\ with 
a history of refractory noncomplitutce 17.x1. 
Of lhc 214 puticnts included. ISI wcrc phtced on the 
waiting list after evulu;uion. 28 were ncccptcd pending 
resolution of minor problems such as smoking. periodontal 
discale or financial negotiations nnd 35 patients wcrc not yet 
able to make the commitmcm tu tran+tntn!iun. ‘fhib was a 
retrospective sludy in which pulicnts undetwcnl lranrpl;mt 
evaluarian. tailored medtcal Ihcrapy and. m sumc cusc\. 
transplanmtion as routinely performed in thix instttution. 
Conscm was uhmincd for the stundard procedures of evalu- 
ittmn and transplantation without separate Human Subjccl 
Cummittcc conrideration. 
Study pa&&. If the routine right heart ctatheterization 
\huwcd twu (1~1s of hcmodgnamic mcasuremcnls scparatcd 
by I h in which the cardiac index wus <2.25 liten/min pcrm’ 
or the pulmonary capillary wcdgc pressure was >?2 mm Hg, 
or both. the pulmonary artery catheter was left in place and 
therapy was ~ywmntically tailored IO achieve hemodynamic 
YouIs UT pulmonsry wedge pressure 5 I5 mm Hp. right atiial 
prcswre <X mm Hg and syslcmic va~ular resistance 
~I.?00 dynes~s~cm~‘. while the systolic blood pressure 
wu< maintained ul z_IIU mm Hp. as previously described 
II .Y-I I I. IO minimize milral regurgilalion. maximize cardiac 
oulpul und improve clinical btatu’i in this group of patients. 
Therapy was begun with nirroprusside. then replaced by 
increasing do\es of oral vilscdilators titrated lo achieve Ihe 
same hemodynamic go&. Al discharge. an angiotensin- 
converting cnzymc inhibitor was prescribed for 108 patients 
and hydralazinc for Y.1: isoaorhide dinilratc was added in 140 
patients. Digoxin wa\ muintaincd to achieve levels of I to 
? ndml. except in pattems with contwindications. No pa- 
licnlr received investigational drugs. Those palients whose 
condition could be >tabilizcd were discharged apcr instrw 
tion regarding a progressive walkinp program and a Bexiblc 
diuretic rcgimcn adjusted according ID daily weight. Subse- 
qucnl oulpaticnt vibilr wcrc inilmlly made weekly. lhcn less 
oflcn aa slubtlity war demonstrated 12). 
Cardiac transplantation. During the same period uf time. 
93 of the ?i4 adult patients underwent cardhc tmncplanta- 
lion after being dixharged II, wait at home. l‘hcrc was no 
provision among oulpatienh for murc compromwd patienls 
Iu receive transplantation firsl: lime on the list was the only 
delcrminanl for the recipient of a given blood lype and hody 
Gc. The surgical procedure. immunosupprcwon (triple- 

Figure 1. Acruarial survival cerves calcula~cd according to ihe 
Kaplan-M&r merhod from the time of evaluation for 214 patients 
discharged on medlcal herapy after tranrplant valuation. a subset 
of 94 padrntr suniving Lhc Isl 4 months akr evaluallon withour 
lransplanfakn ITxl and 88 priemr from Ihe outpalienl waiting list 
ancr lransplantation. Numbers id parenrheses refer 10 palicna 
remaining at Follow-up. Pnrb = probability of. 
ing in death or urgent ~ransplantarion in this group. The 
follow-up period on medical therapy without transplanfation 
extended to 24 months for 27 patients. 
Sarvi-ions versus nonsurvivors. There were no criteria 
that reliably distinguished individual survivors from nonsur- 
vivors al the time of initial hospital discharge (Tables I and 
2). Ejection fraction. history of previous vascdilator therapy 
and initial hemodynamic variables. including filling pros- 
sures. were not di5erent between the two groups. On 
average. orthopnca and right-sided congestion were less 
szverc. wtc;cas scram Esdium *~‘a! sli8htly higher and filling 
pressures achieved after aggressive therapy were lower in 
survivors, who wcrc also slightly older. 
Survival of pslients undergoing Iransplanlniion. Acluarial 
survival of the patients who underwent transplantation after 
waiting 81 home was 88% at I year (Fig. I). comparable to 
that reported for other major programs (3.13l. This survival 
rate is significantly better than the 67% for patients followed 
up on medical therapy (p = O.tYJ91. Death after Iransplanla- 
tion for outpatients was not related IO the time spent waiting 
for a transplant and resulted from posttransplanralion com- 
plicalions of rejec!ion or infection >I month after transplan- 
tation. except in one patient whodied of right heart failure at 
3 days. 
Expected survival after wailing. The actuarial survival 
measured after iransplardation does not reflect the deaths 
occurring in those on the wailing list. Because 75% of the 
deaths during 24 months after evaluation occurred within the 
1st 6 months, the likelihood for survival without rransplan- 
tation improved in outpatients who survived that initial 6 
months. The expected survival for the next I2 months in 
patients who had already survived the 1st 6 months WBP 63% 
(Fig. 1). Fly Y monlhs after evaluation. Ihe projected subsc. 
quent I-year survival was 88%. whether or not transplanta- 
tion was performed nt thal time. 
Figure 2. Improvement in pmbability IProb) of I-year survival 
(Surv) expected after transplantation ITxl for patients wailing at 
home. tie probability of i-year survival with&t transplant&on 
was oblained by recalculating the subsequent I-year actuarial sar- 
viva! rate aitcr each month of survival without transplantation for 
214 patients dircharged after evaluation (see Methods). The ex- 
pecfed survival rate after transplantation was obtained in 88 patients 
who walted at home until transplantation. 
The I-year survival benefit was calculated as the differ- 
ence between the predicted I-year survival rate with trans- 
plantation and that without transplantation recalculated after 
each month already survived on medical therapy tier eval- 
uation (Fig. 2). The expecled benefit decreased as patients 
waited longer until transplantation and WBS not evident at 9 
months. 
Forpurposes of comparison. the I-year survival rate a&r 
transplantation was also calculated for the 64 patients of 
urgent status during the same period who underwent trans- 
plantation while waiting in the hospital during treatment with 
inolropic infusions or mechanical assist devices. Although 
the early operative mortality rate in these patients was 6% (4 
of 64 patients) compared whh only one early death in the 88 
outpatients with Iransplantation. the I-year actuarial SW 
viva1 rate of this group was 64%. which was nar significantly 
different from the 88% in the outpatient group. 
Discussion 
SurvivaL with advanced heart failure. This study of 214 
outpatients wilh hean failure who were potential transplant 
candidates demonstrates thal the major risks are from sud- 
den death. hemodynamic decompensation or an ischemic 
syndrome during the 1st 6 months after referral. Patiems 
who have survived that period of jeopardy without trans- 
planlation arc at much lower risk during the next year; thus. 
the sxvival benefit to be expeeled from transplantation in 
outpaticnls after the 1st 6 months is small compared with 
that gained by critically ill inpatients or that which would lx 
gained by outpalients who underwent transplantation imme- 
diately after evaluation. 
The patients in this study are representative of those 
selected for tran~plantatton by current cri~na in major 
centers (7). Patients with a low ejechon fracrion without a 
history of clinical decompensation were excluded. a, ‘were 
oulpatients with nonischemic cardtomyopathy of reccm on- 
xl. The severity of compromise of cardiac funcrion in the 
selected patients is reflcctcd by the clinical profile. including 
an average ejection fraction of 0.17. serum sodium of 
135 mEq!liter(l4) and class III or IV s>mploma In addition. 
the hemodynamic profile included an average inhial cardiac 
tndcx of 2 literslmin per m’ and pulmonary capillary wedge 
pressure of 26 mm Hg. with those patients wbsequentiy able 
to achieve the lowest filling pressures on therapy having d 
better prognosis. as previously described (IS). Eligible pd. 
tients refusing to accept transplantation were not excluded 
from analysis because they have been shown to babe B high 
mortality rate without transplantation t 161. The earl! mcr- 
tality rale in our palienrs withonl transplantation is compa- 
rable with that of patients awaiting tmnsplantutiun in tiw 
major centers, reported as 9% to 22% in 1986 t 17) whell 
average waiting periods were 4 months. Thus. although the 
data on subsequent outcome without trenzplantation may 
rerrospecriwly identify some patienrs who may noI hew 
needed transplantation when lisred. Ihe decisions made al 
the time of evaluation wcrc in accordw~s Ah current 
standard practice. 
Survival on tailored medical thernpy. As the reporkd 
I-vex wvival rate after trans&mntion t 131 ha, imorowd 
frim 44% ‘0 85%. Ihe survival iate in patienis with a&anced 
heart failure on medical therapy has also improved. In 197R. 
patients accepted for transplantation rho did not undergo 
the procedure had almost no chance of wrvivnl at 6 months 
(IS). Even in a more recent study (19). patients evaluated 
and considered too well for transplantados had poor wrvival 
when subsequent medical cart was noI systematically dc- 
signed and continued. The benelil of empiric vasodilator 
therapy for heart failure has been shown in patient< wtth less 
severe heart failure in the cooperalive Veterans Administra. 
tion trial (201 and the CCNSENSUS trial (211. In many 
patients who do not respond to empirically designed ther- 
apy. therapy wth varodilaton and diuretic drugs tailored to 
hemodynamic goals has allowed hospital discharge and 
prolonged survival without trmsplsnmon (l.!.l5L The 
relative benefit of transplarwion compared with current 
medical therapy should be eslimsxd in group> of patients 
such as those in this study. which excluded patientr ineligi- 
ble for transplsnration becaux vi noncxrdix illness ur 
repeated noncompliance. which would al’io compromise the 
apparent ellicacy of medical therapy. 
Expected benefits of transplantation. For eligible ourpa- 
tients wilh advanced heart Failure. wrviral after transplan- 
ration remains signilicandy belter than that with medical 
therapy. However. the m;ljor r&k for Ihcw patients is during 
the period early after evaluation. wth 7W uf deaths occur- 
rirg during the 1st 6 month\. rcru!ting prlmxily from wdden 
death at home at an avernge Iof 4 momh~ after evalw~~~on. 
Despite concern that longer ~ainn~ umer rwuld resuh in 
more dcrcrwmtiun. decompens;luon leading 10 urgent prior- 
ity trsnsplaatitio~? was not seen after the 131 6 months from 
evaluation. The relatively high morrality rate early after 
referral ha> iwen previausly described 14) in pausms r\ith 
heart faiiure. 
Survival curve% wth and without tranbplantalion arc 
cr~~tumarli~ compared by starting with the ume of trjnaplan- 
tation for recipiemr: thw. the mortality of patients on the 
wairin~ 1;~ for transplantation is overlooked. Theo omission 
ha> reAred in owreswnation of the acwl beneM of ~rdns- 
planration for ourpaiienrs. as currenlly prcvidcd in thi? era of 
a evereiy limit4 donor heart supply and long warring lists. 
The bcn& fur outpatients is not the eapecled increase in the 
I-year -rtirGv:d rate from 67% to 88% thal would result if all 
p;ttient> underuent transplantation at the time of accep 
:~mce. Instead. wth an average waiting time approaching 6 
moniha. the mcrease expected for rhe average parienr wait- 
ing itt home uould only be from 83% to 88% and would be 
wcn lcs 1s rke waiting IisIs cominue to grow. 
If the curviwd benefit is less than initAly projected for 
the waning li\t survivor. *haI are the benefits olfered by 
It-~nsplantdt!on for functional status and quality of life’? II has 
previously been shown (2.5) thal many patients wnose 
cwdiwn CM bc >idb.bilized an medical therapy after evalua- 
tlotl aChv?Vc an ewrcibe cupachy and srlf-assssscd qudity oi 
life after I ycx that are. although less than those of healthy 
mdiGduals. simi!dr to those achieved by A comparable group 
of paricnlk undergoing lranspiantation. Outpalients wirh 
more severe functional compromise Ihat persists despite 
prulongcd wvival while on a waiting list arc eexn!ly 
identified by refrxtory fluid rewnhon unresp~nwe to a 
‘.r.rible dureric regimen. objective exercise tcrting that 
reveals pc.A oxygen consumption <I2 to I4 mliks per min 
1221 or. in some cabes, by ~nconrrollable angina or yympto- 
maric vrnrricular arrhythmias. 
Outpatients versus hmpilaliaed patients. This limited hen 
eilr for the average survivor on a wailmg lisl contrasts 
41~ply with that gained by pAems who remain hospitalized 
in critical condition until urgent transplantation can be 
pertormed. By definition of urgent status. such patients have 
a life expectancy of hours or days without transplantation. 
Furthermore. the funclional stilfus and quality of life are 
obviously unacceptable for such patients. who are bed 
hound end dependent on intenswe hospital support with 
intravenouc infusions or temporary mechanical devices. 
Even though such patients may have a slightly higher 
postopemlive mortality rate. their overall survival is cur- 
rently compamhle 10 that of outpatient candidates. both in 
this wdy and in others (23). if seleclion is carefully per- 
formed. Thus rransplamation offers a much larger benefit in 
terms of both wrvival and function when performed in 
crnically III par~cntr than in outpatients on the current 
wainng lists. 
Limitations. This study is limited by the relarivrly small 
number ofpaticnts available for 2 years of follow-up Ahout 
rransplamation. This limhation is inherent in any study of 
potemial ~ranspl;mt candidate. many of whom will eventu- 
ally rccewe an appropriate donor heart and then be removed 
from the group of palients with heart failure on medical 
therapy. This rtudy was not designed to identify specific risk 
factors for death in advanced hearl failure. which have been 
previously :iddressed (!5.?2.24-261. In addition, it was not 
des~ned to demonstrate the efficacy of various medical 
regmtcns. Itwead. it was performed IO tell the hypothesis 
that the expected survival benet% from transplantation de- 
creases as waiung time mcreases for outpatient candidates 
receiving tailored medical therapy. as currently available. 
front the time of lransplant evaluation. 
fmplicaticns fur candidate selection. The results of this 
study support the current pohcy of awarding higher priority 
to cr;tncally 111 Inpetienrs who nre otherwise eligible than to 
waiting outpaticnls 127). in whom the expected benefits are 
Iowcc. However. the majority of pntients listed and a slightly 
smaller majority of patients undergoing transplantation are 
outpatients 13). Among rhese palienls. the waiting list time is 
currently the major factor in priority. a policy nol supported 
by this study. 
Det~hi~w~ w~urrlin~ rlrr sr~lecrro~t and priorirvfor w~pcr- 
~wnf rrrrrr,~/,/onfu/io,l H orrld he fircilimred if it were possible 
to identify those patients in greatest jeopardy for deteriora- 
tion or death while on a wailing list. The patienls with 
obvious hemodynamic instability that persists after adjust- 
ment of therapy during trimsplant evaluation are al greatest 
risk for hcmodynamic deterioration. are easily identified 121 
and are often rehospitalized before transplantation. How- 
ever. for those patients whose condition can be stabilized. 
Ihe major nsk IS ofaudden death r~lher than late circulator,’ 
decompensation (2.15.22.28~. Allhough mulliplc risk facws 
for sudden death have been identified. such ab low ejection 
fraction due IO coronary artery disease (15). persistent high 
ventticr!ar filling pressures despile aggressive therapy IIS). 
low exercise tolerance (22.25). low serum sodium 114). atrial 
fibrillation (24) and history of previous cardiac arrest (19.30). 
these variables are less useful criteria for an individual 
patient than for group4 of patients. The use of programmed 
electrical stimulation or signal-averaged electrocardiography 
has not identified the majority of patients al risk (31.32). 
There are diverse causes of the sudden deaths that occur in 
patients with heart failure (331. for whom there is not 
adequate information at this time regarding the benefit of 
specific therapies aimed at prevention. 
Tk nhi/i~.v 10 htww srkcr ~hosc orrlprrriotrs nr kiglwsr 
rbkJ~,r srrddm dmh. despite currenlly available drugs and 
devices. would allow us to award them a higher priorily for 
lransplantalion. If their waiting limes were short. the waiting 
list mortality rate tiould be reduced and the expected 
survival benefit would be realized. Until we can better select 
outpatients at risk. however. the informalion provided by 
the gnm natural selection process of the waiting !ist should 
not be ignored. Those patients who survive for :. rro&s 
without transpl;.qtation deserve specific reevaluation. rather 
than receiving a hiy’ter priority. Persislenl hemodynzmic 
instability. angina or low maximal oxygen consumption may 
indicate the continued need for transplantation (2.22). How- 
ever. in the absence of these facwrs, patients surviving for 6 
months may not derive substantial benefit in functional 
capacity or wvival from late transplantation. 
The psycho&c price paid by ~nnsplanf condidares on o 
~erritinr list is high. There is a natural reluctance on the part 
of both physician and patient to retnow from the transplant 
list a candidale whose life has been disrupted by the possi- 
bility of imminent transplantation. However, patients whose 
condition has been stable for 6 months often ask if trans- 
plantation is still necessary. For these survivors. the timing 
of transplantation is crucial not only to ensure that the 
procedure offers them sutlicient immediate benefits. but aI90 
to mwimize Iheir total life expectancy (prelransplant plus 
posllransplant) because long-term survival afler transplanta- 
tion i:. limited by the graft atherosclerosis that at&% almost 
50% of recipients by 3 years (341. 
There are currently twice as many heart transplant can- 
didales joining the U.S. waiting list each month as there are 
patienlsactutdly undergoing transplantation (27). Criteria for 
selection and timing of transplantation must evolve IO reflect 
the increasing impact of this resource limitation 05). To 
maximize the value ofcardiac transplantation, we must learn 
how lo berl match the few available hearts with those 
recipients mosl likely lo derive major benefit. 
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